Bulevirtide for hepatitis D: bile acids and gut bacteria
Part of Cancer, Digestive system, Immune system & allergy, Infections clinical trials.
This study looks at how Bulevirtide, a treatment for hepatitis D, affects bile acids and gut bacteria. It may help patients with chronic HDV and stable liver disease who are already on HBV therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have chronic hepatitis D with stable liver disease (Child-Pugh class A)
- You have had a positive HDV RNA test in the last 6 months
- You are already taking medication for hepatitis B
- You are starting Bulevirtide within 30 days of joining the study
- You are 18 or older and have not taken antibiotics, probiotics, or prebiotics in the past month
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a daily shot of Bulevirtide for people with long-term hepatitis delta and early-stage cirrhosis. It aims to see if the medicine is safe and works well.
This study tests a drug called bulevirtide for people with chronic hepatitis B and D co-infection. It aims to see if the drug is safe and effective, and to study biomarkers that may help predict how well it works.
This trial tests a drug called bulevirtide for people with chronic hepatitis B and D (HDV) co-infection. It looks at how the immune system and virus respond to treatment.
This study looks at mouth health in people with hepatitis B and D, including those taking a medicine called bulevirtide and those not taking it. It may help understand how these infections affect the mouth and gums.
This trial tests a new drug, brelovitug, against an existing one, bulevirtide, for people with chronic hepatitis delta. It aims to find a better treatment to lower the virus and protect the liver.
This trial tests if switching from bulevirtide to brelovitug can help people with chronic hepatitis D (CHD). It is for adults who have been on bulevirtide for at least 6 months and still have detectable virus.
Hear when a new HBV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.